Author:
Hu Xiaoxia,Zhao Hui,Wang Youzhi,Liu Zhan,Feng Bainian,Tang Chunlei
Funder
National First-class Discipline Program of Food Science and Technology
National Natural Science Foundation of China
Subject
Organic Chemistry,Clinical Biochemistry,Drug Discovery,Pharmaceutical Science,Molecular Biology,Molecular Medicine,Biochemistry
Reference19 articles.
1. The history and future of targeting cyclin-dependent kinases in cancer therapy;Asghar;Nat Rev Drug Discovery,2015
2. Cell cycle, cytoskeleton dynamics and beyond: the many functions of cyclins and CDK inhibitors;Bendris;Cell Cycle,2015
3. Molecular pathways: CDK4 inhibitors for cancer therapy;Dickson;Clin Cancer Res,2014
4. Clinical potential of novel therapeutic targets in breast cancer: CDK4/6, Src, JAK/STAT, PARP, HDAC, and PI3K/AKT/mTOR pathways;Hosford;Pharmacogenomics Pers Med,2014
5. Dual targeting of CDK and tropomyosin receptor kinase families by the oral inhibitor PHA-848125, an agent with broad-spectrum antitumor efficacy;Albanese;Mol Cancer Ther,2010
Cited by
9 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献